Sol-Gel Technologies Ltd. (SLGL): Price and Financial Metrics


Sol-Gel Technologies Ltd. (SLGL): $12.00

-0.11 (-0.91%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SLGL POWR Grades


  • Sentiment is the dimension where SLGL ranks best; there it ranks ahead of 96.2% of US stocks.
  • SLGL's strongest trending metric is Momentum; it's been moving down over the last 206 days.
  • SLGL's current lowest rank is in the Momentum metric (where it is better than 11.51% of US stocks).

SLGL Stock Summary

  • The ratio of debt to operating expenses for Sol-Gel Technologies Ltd is higher than it is for about merely 8.65% of US stocks.
  • With a price/sales ratio of 30.03, Sol-Gel Technologies Ltd has a higher such ratio than 93.03% of stocks in our set.
  • Revenue growth over the past 12 months for Sol-Gel Technologies Ltd comes in at -61.7%, a number that bests only 4.82% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Sol-Gel Technologies Ltd are SEAC, SRTS, INTZ, UTSI, and KMDA.
  • SLGL's SEC filings can be seen here. And to visit Sol-Gel Technologies Ltd's official web site, go to www.sol-gel.com.

SLGL Price Target

For more insight on analysts targets of SLGL, see our SLGL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $20.00 Average Broker Recommendation 1.25 (Strong Buy)

SLGL Stock Price Chart Interactive Chart >

Price chart for SLGL

SLGL Price/Volume Stats

Current price $12.00 52-week high $16.69
Prev. close $12.11 52-week low $7.00
Day low $11.52 Volume 439,346
Day high $14.50 Avg. volume 50,889
50-day MA $11.46 Dividend yield N/A
200-day MA $10.46 Market Cap 244.68M

Sol-Gel Technologies Ltd. (SLGL) Company Bio


Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company’s lead product candidates include VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea; and TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris. It is also involved in the development of generic dermatological candidates; and formulation and pre-clinical development of early stage product candidates for acne and rosacea, and other dermatological indications. The company was founded in 1997 and is based in Ness Ziona, Israel


SLGL Latest News Stream


Event/Time News Detail
Loading, please wait...

SLGL Latest Social Stream


Loading social stream, please wait...

View Full SLGL Social Stream

Latest SLGL News From Around the Web

Below are the latest news stories about Sol-Gel Technologies Ltd that investors may wish to consider to help them evaluate SLGL as an investment opportunity.

Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021

NESS ZIONA, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2021 financial results on Wednesday, August 4, 2021 at 7:05 AM ET. About Sol-Gel Technologies Sol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded a

Yahoo | July 20, 2021

Sol-Gel Announces Pipeline Update and Future Development Plans

Sol-Gel investigational SGT-510 was found to be more effective than roflumilast cream, 0.3%, in a human xenograft psoriasis animal modelSol-Gel is developing tapinarof cream, 1%, aiming to offer product formulation innovations and increased affordability for patients compared to the brand expected to be launchedOur proof-of-concept study for SGT-210 (erlotinib gel) in palmoplantar keratoderma patients has been completed and indicated a possible modest improvementSol-Gel to host Conference Call t

Yahoo | June 28, 2021

Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States

NESS ZIONA, Israel & LAUSANNE, Switzerland, June 28, 2021--Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, and Galderma, the world’s largest independent dermatology company, today announced they have signed two exclusive 5-year license agreements for the commercialization of EPSOLAY® and TWYNEO® in the United States.

Yahoo | June 28, 2021

Sol-Gel Technologies to Present at Upcoming Jefferies Healthcare Conference and Raymond James Human Health Innovation Conference

NESS ZIONA, Israel, May 27, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company will present a Company overview and business update at the following upcoming virtual investor conferences: Jefferies Healthcare Conference (June 1 – 4, 2021)Speaker:Dr. Alon Seri-Levy, Chief Executive OfficerDate:Tuesday, June 1, 2021Time:8:30 – 8:55 am EDT Raymond James Human Health Innovation Conference (June 21 – 23, 2021)Speaker:Dr. Alon Seri-Levy, Chief Executive OfficerDate:Tuesday, June 22, 2021Time:10:00 – 10:30 am EDT A recording of the webcast of each presentation will ...

Yahoo | May 27, 2021

Raymond James: These 3 Stocks Are Poised to Surge by at Least 50%

In a recent note on the state of the stock markets, Raymond James equity strategist Tavis McCourt points out a series of policy factors that are playing a role in the current market volatility; the situation is more complex, perhaps, than most of us have been willing to admit. McCourt notes permutations of the SLR rule, political dynamics on the Senate Banking Committee, and the regulatory atmosphere towards potential capital return are all influencing the Fed’s moves and the market reactions.

Michael Marcus on TipRanks | March 10, 2021

Read More 'SLGL' Stories Here

SLGL Price Returns

1-mo -9.50%
3-mo 0.00%
6-mo 21.21%
1-year 67.60%
3-year 84.62%
5-year N/A
YTD 22.57%
2020 -42.92%
2019 184.88%
2018 N/A
2017 N/A
2016 N/A

Continue Researching SLGL

Want to see what other sources are saying about Sol-Gel Technologies Ltd's financials and stock price? Try the links below:

Sol-Gel Technologies Ltd (SLGL) Stock Price | Nasdaq
Sol-Gel Technologies Ltd (SLGL) Stock Quote, History and News - Yahoo Finance
Sol-Gel Technologies Ltd (SLGL) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0707 seconds.